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Abstract 
Objective 
The impact of antithrombotic agents on primary intracerebral hemorrhage (ICH) patients 
remains controversial, especially with patients that require emergent craniotomy. This study 
was to evaluate clinical outcomes in operated ICH patients with and without prior 
antithrombotic agents. 
 
Methods 
This is a retrospective cohort study. Between January 2001 to December 2013, all ICH 
patients that received emergent craniotomy and is present in Taiwan’s National Health 
Insurance Research Database were screened, and divided into prior antiplatelet therapy, 
anticoagulant therapy and non-antithrombotic therapy according to patient's healthcare claims 
data within 3 months of index admission. The primary endpoints included in-hospital mortality 
and complication, and short-term outcome. 
 
Results 
Of 18,872 eligible patients, 16,251 (87.1%) patients did not receive any antithrombotic therapy, 
2,267 patients had antiplatelet therapy and 354 patients had anticoagulation therapy. After 
propensity score matching, significantly higher amount of blood transfusion and number of 
craniectomy was identified in the patients with prior antithrombotic treatment compared with 
non-antithrombotic therapy. In comparison with the non-antithrombotic treatment cohort, 
patients under prior anticoagulant treatment had significantly higher in-hospital mortality rate 
(Odds ratio, 2.12; 95% confidence interval, 1.45–3.10). Furthermore, during the 6-month 
follow-up period, prior anticoagulant therapy was independently associated with a greater risk 
of all-cause mortality rates (P = 0.001). Interestingly, the in-hospital and 6-month all-cause 
mortality of patients with prior antiplatelet treatment was not significantly different to patients 
with non-antithrombotic treatment. 
 
Conclusion 
These findings suggested an increased risk of in-hospital mortality and poor short-term 
outcome among operated ICH patients with prior antithrombotic therapy, particularly 
anticoagulant therapy, but not with antiplatelet therapy. 
 
.  
Introduction 
Spontaneous intracerebral haemorrhage (ICH) accounts for 10 - 15% of all cerebrovascular 
accident, and exhibit a higher mortality rate than either ischaemic stroke or subarachnoid 
haemorrhage 1. Recently, antithrombotic agents, including antiplatelet therapy such as aspirin 
and anticoagulants such as warfarin, have been widely prescribed for patients as secondary 
prevention of coronary heart- or thrombotic-related disease 2,3. Therefore, it is more becoming 
common for patients prior to ICH to have previously been exposed to antithrombotic agents. 
It has been previously suggested that patients with exposure to antithrombotic agents prior 
ICH would have a higher risk of secondary hematoma expansion, and an increased risk of 
death, or poor functional outcome 4,5. Therefore, one essential problem frequently encountered 
clinically is how to manage patients on antithrombotic agents following spontaneous ICH, 
especially those requiring craniotomy. 
Craniotomy is a life-saving procedure regularly carried out in selected patients with 
spontaneous ICH, but the presence of antithrombotic agents may increase the possibility of 
postoperative haemorrhage, as well as complication and mortality following craniotomy6. 
Therefore, the dilemma in treating ICH patients on antithrombotic agents will be the risk of 
increasing blood loss during surgical intervention versus the risk of further secondary brain 
damage if the hematoma is not removed.  
To date, the impact of antithrombotic effect on mortality and complicated rate after surgical 
intervention in spontaneous ICH has not been sufficiently accessed because of limited number 
of operated ICH patients. According to national cohort studies, there are only 6.9 - 7.9 % 
patients with ICH receiving hematoma evacuation 7,8. Interestingly, since the incidence of ICH 
is much higher in Asian rather than non-Asian population 9. Therefore, it provides us with an 
opportunity to evaluate the impact of antithrombotic agents on the clinical outcomes of Asian 
ICH patients requiring hematoma evacuation. In this study, we examined the hypothesis that 
antithrombotic agents provide unfavourable in-hospital and short-term outcomes for ICH 
patients requiring craniotomy from the National Health Insurance Research Database (NHIRD) 
of Taiwan.  
  
Method 
Data source 
This retrospective-collected and observational cohort study involved data obtained from 
Taiwan’s National Health Insurance Research Database (NHIRD), which contains all 
healthcare claims data between Jan 1997 to December 2013, include demographic data, 
records of clinical visits, hospital admissions, prescriptions, and disease status for more than 
99% of the Taiwanese population. Data were anonymized, encrypted and maintained by the 
National Health Research Institutes of Taiwan for research purposes. Diagnostic codes used 
in the database are based on the international classification of disease, ninth revision; clinical 
modification (ICD-9-CM) codes (Supplementary Table 1). Validation of the NHIRD data 
involving cerebrovascular accident have been demonstrated in several studies by NHI Bureau 
10,11. This study was exempt from approval requirements by the Institutional Review Board of 
Chang Gung Memorial Hospital in Taiwan (IRB number, 201601518B0) and without 
permission of patient’s consent, given that it was an epidemiology study with no definable 
patient information. 
 
Subjects 
Study patients were identified from the NHIRD as those admitted for first event of 
cerebrovascular accident from January 1, 2001 and December 31, 2013 (ICD-9 CM codes, 
430–437) (Supplementary Table 1). Within these patients with cerebrovascular accident, those 
who were diagnosed as a spontaneous intracerebral haemorrhage were identified (ICH, ICD-
9-CM code, 431). The date of the first admission for ICH was assigned as the index date. 
Patients younger than 20 years, and those diagnosed with cerebral vascular lesion, such as 
arteriovenous malformation, aneurysm were excluded (ICD-9-CM codes, 437.3, 747.81, 4470). 
We also excluded the comorbidities where the conditions can possibly interfere with 
coagulation conditions, such as coagulopathy (ICD 9-CM codes, 286.0–286.9, 287.1, 287.3–
287.5, 289.81–289.82), liver cirrhosis (ICD-9-CM codes, 571.2, 571.5, 571.6), malignancy 
(ICD-9 CM codes, 140.xx–208.xx) predating the index date. To ensure that ICH were not 
secondary to other events, we also excluded those who suffered head injury (ICD-9-CM codes, 
800.xx–804.xx, 850.xx–854.xx), haemorrhage stroke (ICD-9-CM codes, 430.xx–432.xx), and 
brain surgery events within 6 months before the index date. Overall, patients which received 
craniotomy during the index ICH admission data were eligible for selection into our study. 
 
Exposure of antithrombotic therapy and study design 
In order to compare the impact of antiplatelet and anticoagulant regiment on those receiving 
craniotomy, we retrieved the patient's healthcare claims data within 3 months of index 
admission. According to prescription record system, we exclude those under dual antiplatelet 
treatment. Eligible patients were further divided into three groups according to the 
antithrombotic agents exposure including; (1) no antithrombotic therapy, (2) antiplatelet 
therapy (e.g. aspirin, clopidogrel and ticlopidine), (3) anticoagulant therapy (e.g. warfarin and 
new oral anticoagulants (NOACs) including dabigatran and rivaroxaban). In order to balance 
all possible confounding factors between groups, propensity score matching (PSM) method 
with 1:1 matching between groups was performed prior analysis of clinical outcomes (Figure 
1). 
 
Outcomes measures and comorbidities 
Baseline comorbidities, in-hospital complications and short-term outcomes were identified 
based on ICD-9-CM diagnosis codes recorded during hospitalization or clinic visit 
(Supplementary Table 1). The Charlson comorbidity index (CCI) was calculated to measure 
the patient’s underlying condition. Selected comorbidities were ascertained based on one in-
patient diagnosis or at least 2 outpatient diagnoses one year before index date. History of 
event (i.e. stroke, myocardial infarction) was verified using in-patient diagnosis before index 
date and tracked back to year 1997. In order to assess the severity of haemorrhagic stroke, 
estimated National Institute of Health Stroke Scale (NIHSS) based on weighted evaluation 
findings was applied, which was validation in a previous NHIRD study 12. The primary outcome 
of this study was in-hospital mortality during the index admission. In-hospital treatment 
(including neurosurgical procedure and volume of blood transfusion) and postoperative 
conditions (including ischaemic stroke, pneumonia, septicaemia, surgical wound infection, 
pulmonary embolism, deep venous thrombosis, acute kidney injury, and massive blood 
transfusion) during the index admission were secondary outcomes. The short-term 6-month 
all-cause mortality were identified according to the withdrawal from the NHI system 13. Data of 
patients were censored in the date of event occurrence, date of death or before 31 December, 
2013.  
 
Ascertainment of ICH, comorbidities and Outcomes 
A majority of comorbidities based on ICD-9-CM have previously been validated 14,15. The study 
patients with ICH were selected when their principal diagnosis of index hospitalization was 
ICH ([ICD-9-CM] code: 431). The high accuracy of the diagnosis of ICH based on ICD-9-CM 
coding in the NHIRD has been confirmed in a previous study 16. Furthermore, a validation 
study was conducted in one centre by randomly sampling the records of 119 hospitalized 
patients in which their principal diagnosis of hospitalization was coded as ICD-9-CM: 431. A 
positive predictive value of 98% (117/119) was obtained when their medical records and 
images were independently reviewed by a physician (C-H Liu).  
Statistical analysis 
The distributions of demographic and clinical characteristics were compared between the 
three study groups using chi-square test for categorical variable or one-way analysis of 
variance for continuous variable. Bonferroni adjustment was made as to the pairwise 
comparisons when the overall test was significant. Risk factors associated with in-hospital 
mortality were studied using multivariable logistic regression analysis. A propensity score 
matching (PSM) analysis was performed before comparing outcomes among the prior 
antiplatelet, anticoagulant, and non-antithrombotic groups, to ensure that the baseline 
characteristics among these three groups would be comparable (Supplementary Tables 2-4). 
The selected covariates used to calculate the propensity scores were gender, ages, hospital 
level where the operation was performed, coexisting diseases, history of event, CCI 
comorbidity, estimated NIHSS score and the index date. A 1:1 matching ratio was chosen in 
which greedy nearest neighbour algorithm was adopted and the caliper was set as 0.2 times 
the standard deviation of the logit of propensity score 17. Comparison in blood transfusion 
volume between any two PSM groups was made using generalized estimating equation (GEE) 
type linear regression. Furthermore, comparison of risk of in-hospital treatment (neurosurgical 
procedures), in-hospital complication and mortality between any two PSM groups were made 
using GEE type logistic regression. The correlation of patients among the same match pair 
was adjusted in GEE model. The risk of time to all-cause mortality was compared within the 
three study groups before PSM using pairwise log-rank test. Likewise, the survival curves 
during the 6-month follow up were compared between any two PSM groups by using log-rank 
test stratified by match pair. Level of statistical significance were set as 0.05 and no adjustment 
of multiple testing (multiplicity) was made in this study. The data analysis were conducted 
using SAS software version 9.4 (SAS Institute, Cary, NC). 
  
Result 
Patient characteristics  
From an initial sample of 699,291 patients with cerebrovascular accident events during the 13 
year period between January 1, 2001 and December 31, 2013, there were 114,219 patients 
admitted for spontaneous ICH in Taiwan. After applying a series of excluding criteria, a total 
eligible 18,872 ICH adult patients were included, of which 2,267 (12 %) and 354 (1.9 %) 
received antiplatelet or anticoagulant treatment prior surgical intervention, respectively (Figure 
1, Table 1). The mean age for the overall cohort was 59.7 years with a predominant male 
gender (66.5 %). 
There were several significant differences in the baseline demographics and clinical 
characteristics of the study patients (Table 1). The mean age in the control group (58.6 years) 
was significantly younger compared to that in the antiplatelet (66.6 years) and anticoagulant 
(65.3 years) groups. Patients with anticoagulant therapy (54.5 %) were significantly more likely 
to receive craniotomy in teaching hospital than the antiplatelet (38.9 %) or control (36.9 %) 
groups. In general, patients underwent antithrombotic or anticoagulant regimens had a 
significantly higher prevalence of all major medical comorbidities (i.e., atrial fibrillation, 
hypertension, chronic kidney disease), and history of event (i.e., ischaemic stroke) compared 
to control patients. Noticeably, the prevalence of atrial fibrillation was significantly higher in the 
anticoagulant group (46.3 %) than that in the antiplatelet group (6.4 %). 
 
Events during index hospitalization 
In addition to craniotomy, further neurosurgical intervention and in-hospital blood transfusion 
were studied (Table 2 and 3). There was a trend toward increasing number of craniectomy 
following craniotomy in patients receiving antiplatelet treatment when compared with no prior 
antithrombotic therapy. Patients under anticoagulant were significantly more likely to receive 
craniectomy than those with prior antiplatelet treatment (odds ratio [OR], 2.21; 95% confidence 
interval [CI], 1.25 – 3.93) (Table 3). No significant difference was observed among the three 
groups with respect to other further surgical interventions (i.e. repeated brain surgery, extra-
ventricular drainage) during the index admission. In contrast, greater amount of platelet during 
blood transfusion was required in the antiplatelet group than that in the control group 
(regression coefficient, 0.70 unit; 95% CI, 0.28 – 1.12) (Table 3). Furthermore, administration 
of fresh frozen plasma was significantly less in the antiplatelet than the other two groups. 
Interestingly, packed red blood cell usage was significantly higher in the anticoagulant than 
antiplatelet group, and that both groups were greater than non-antithrombotic (control) group. 
To understand the in-hospital complications, the complications after craniotomy were divided 
into the following categories: pulmonary, septicemia, wound infection, thromboembolic, 
postoperative haemorrhage, neurologic, and renal issues (Table 2 and 4). The order of 
greatest common complication (greatest number first with percentage of occurrence ≥ 4 %) 
was pneumonia, septicemia and ischaemic stroke. In comparison to the control group, there 
was no significant difference between surgical-related complications in the two antithrombotic 
groups. Interestingly, patients in the anticoagulant group were significantly more likely to suffer 
septicemia compared to those in the antiplatelet group (OR, 2.29; 95 % CI, 1.10 – 4.76) (Table 
4). Furthermore, patients under anticoagulant treatment have significantly higher in-hospital 
mortality rate compared to the antiplatelet group (OR, 1.60; 95 % CI, 1.12 –2.30) and to the 
control group (OR, 2.12; 95 % CI, 1.45 – 3.10). However, the in-hospital mortality rate was not 
significantly different between the antiplatelet group and the control group. 
Additional analysis was carried out to investigate risk factors of in-hospital mortality by using 
the whole cohort. The result identified the following variables as potential risk factors: male 
gender, age greater than 80 years (compared to 20-39 years), operation in non-teaching 
hospital, atrial fibrillation, epilepsy, hypertension, diabetes mellitus, coronary artery disease, 
chronic kidney disease and history of ischaemic stroke (Figure 2). 
Outcomes during Follow-up 
Mortality rate of the three groups of patients during the 6 months follow-up period was studied 
in the whole cohort (Figures 3A). The all-cause mortality rates at 6 months follow up of control, 
antiplatelet, and anticoagulant patients were 9.9 %, 13.6 %, and 19.9 %, respectively. Large 
significant differences in the survival curves between all the three groups were observed 
(Figure 3A). Furthermore, the 6 months mortality rate was significantly higher toward the 
anticoagulant group compared to the control and the antiplatelet groups when using the PSM 
cohorts (p = 0.001, p = 0.007, respectively) (Figures 3B and C). However, the 6 month mortality 
rate was not significantly different between the antiplatelet and the control groups when using 
the PSM cohorts (P = 0.773, Figure 3D). 
  
Discussion 
The use of antithrombotic agents in the general population is ever increasing due to their 
preventative use for a variety of disease such as cardiovascular disease. Therefore, it is 
important to understand their impact in emergency neurological surgery. In this study, we 
compared 18,872 patients that have received craniotomy after spontaneous ICH in a 13 year 
period with matched control group by using the Taiwan’s health nationwide database. Our 
study showed the incidence of ICH receiving craniotomy was 16.5 %. To date, this is the 
largest cohort study of craniotomy for ICH. Furthermore, this study compares the admission 
events, in-hospital mortality and 6-months outcome of patients receiving prior antithrombotic 
therapy with those of a matched control group. We demonstrated significant increased in-
hospital mortality in operated ICH patients receiving prior anti-coagulant treatment, but not in 
patients with prior anti-platelet treatment. 
 
Impact of antiplatelet therapy  
Currently, the influence of prior antiplatelet therapy has on ICH expansion or neurologic 
outcome remains controversial 5,18,19. A recent study revealed that a pre-hospital antiplatelet 
regimen could be associated with hematoma expansion, an increased mortality rate, and poor 
functional outcome in spontaneous ICH 5,8. In contrast, other studies have failed to detect 
differences in outcome or hematoma growth 18,19. The reason for this discrepancy is not clear, 
but this could be due to the heterogeneous clinical presentations of ICH, different treatment 
strategies and low incident rate.  
A recent study demonstrated a significant higher risk of in-hospital mortality after hematoma 
evacuations in patients with prior antiplatelet treatment compared to patients without prior 
antiplatelet treatment 20. From our real-world data, the in-hospital mortality and short-term 
outcome of patients with prior antiplatelet treatment was significantly increased compared to 
control group (Figure 3A). However, in-hospital and 6 months mortality revealed no significant 
difference after matched control comparison (Figure 3D). This implies that the underlying 
condition of patients receiving antiplatelet plays a vital role in the clinical outcome.  
 
Impact of anticoagulation therapy 
It has been previously shown that the mortality and neurologic outcome were worse for 
anticoagulant associated ICH. This could be due to larger haemorrhage volumes 21,22, higher 
risk of hematoma expansion 4, and higher comorbidities among anticoagulated patients 23. 
Interestingly, this worsening in neurological outcome may be associated with the patients’ race, 
since a recent study demonstrated that haemorrhagic stroke rates were higher in Asians 
compared to non-Asians on warfarin 24. In line with previous studies, our study observed pre-
treatment with oral anticoagulant was a strong predictor of increased in-hospital mortality 25,26. 
Furthermore, we found the rate of complication was significantly higher among patients 
receiving prior anticoagulant therapy compared to control and antiplatelet group. Interestingly, 
a recent study demonstrated that oral anticoagulants did not increase in-hospital mortality in 
ICH patients receiving hematoma evacuation because the international normalized ratio could 
be normalized before surgical intervention 27. This discrepancy could be explained by the racial 
difference in warfarin pharmacokinetics. Asian population in particular have a higher risk for 
warfarin-related ICH 28. The optimal range of international normalized ratio for Asians might 
be narrower than for non-Asians, which could lead to difficult control on anticoagulation quality 
29. Current data suggest that the NOACs are not associated with a higher risk of spontaneous 
ICH 30. However, since this is a relative new therapy, the number of patients that have received 
NOACs in our study was too low for any meaningful statistical analysis. 
 
Surgical outcome of ICH with prior antithrombotic treatment 
The findings from our study demonstrated that patients taking prior antithrombotic treatment 
required a greater number of decompression craniectomy. Our finding suggested the brain 
edema developed more frequently in the patients treated with antithrombotic. Another possible 
reason could be related to the significantly more blood transfusion performed in these patients. 
It should be noted that although complications of blood transfusion are rare, it can be life 
threatening because massive blood transfusions can result in abnormalities of coagulation 
status, vascular permeability, acid-base balance and temperature hemostasis 31. Previous 
studies have demonstrated that the large quantity of blood transfusions can cause 
complications such as reversible posterior leukoencephalopathy syndrome 32-34. Furthermore, 
blood transfusion may cause a rapid increase in total blood volume, which further leads to 
cerebral blood flow overload. It has been suggested that an abrupt or acute cerebral 
hyperperfusion exceeding the capacity of autoregulation of cerebral capillary perfusion 
pressure could result in vasogenic edema34. 
Surgical complication associated with antithrombotic treatment 
The three most common surgical complications in our study were pneumonia, septicaemia, 
and gastrointestinal bleeding. This was not surprising, since stroke patients have been 
demonstrated to be more susceptible to infection due to immune system suppression 35. 
Pneumonia was the most common complication in our study, which is consistent with other 
studies on stroke patients 36. Interestingly, pneumonia and septicaemia that required medical 
treatment were present more often in patients with prior anticoagulant treatment. Overall, 
patients receiving prior anticoagulant therapy have higher complication rate compared to 
either antiplatelet or non-antithrombotic therapy.  
 
Limitation of the study 
The presented data were analyzed from the Taiwan’s national wide database and was not a 
randomized trial for operative treatment ICH patients. Therefore, there was no prospectively 
document to suggest the reason why a craniotomy was necessary, so presumption was made 
that haemorrhage enlargement would led to a worse neurologic exam, such as a potential 
brain herniation. Additionally, the database does not include neurological or functional 
outcome, such as Glasgow Coma Scale, or modified Rankin Scale, respectively. However, the 
absence of such data does not lessen our data interpretation. Another consideration should 
be taken is that clinicians may not be blinded to antiplatelet or anticoagulant treatment prior to 
ICH development, so these data reflect an association between these medical treatments and 
the perceived need for craniotomy. The strengths of our study includes; 1) a large population-
based follow-up study containing all adults living in Taiwan, 2) usage of estimated NIHSS 
which has already been well assessed to correlation of severity of ICH patients, and 3) the 
integrated details of prescription records prior to admission, complications, mortality and 
clinical following-up were well recorded. Furthermore, the analysis of propensity score 
matching was applied to eliminate the confounding factors among these patients.  
  
Conclusions 
This study has provided a comprehensive national perspective on in-hospital complication and 
mortality in operative ICH patients in Taiwan. Prior antithrombotic agent treatment in ICH 
patients receiving craniotomy was associated with an increased risk of repeated brain surgery. 
Furthermore, our study also identified the significantly higher in-hospital mortality and six 
months all-cause mortality rate in patients with prior anticoagulant therapy, but not in patients 
with prior antiplatelet therapy. In summary, physicians should be more aware of the potential 
risk with prior antithrombotic therapy, especially anticoagulant treatment and their negative 
association with life-saving surgical intervention for spontaneous ICH. This is valuable 
information for surgeons faced with difficult decision in managing patients taking 
antithrombotic drugs, but requiring neurosurgical intervention.  
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Figure legends 
Figure 1 Flow chart illustrating the patient selection included in the study. 
Flow chart illustrating the patient selection included in the study. (A) Spontaneous ICH patients 
receiving craniotomy were divided into three groups (control, antiplatelet, and anticoagulant) 
according to the prior antithrombotic therapy. Patients with cerebrovascular accident admitted 
for hemorrhage stroke were included after relevant exclusions. (B) Propensity score matching 
with a 1:1 ratio enable 3 groups of comparisons with their number of patients. 
 
Figure 2 Association of patient characteristics with risk of in hospital mortality. 
This multivariable logistic regression analysis was adjusted for all variables listed in Table 1. 
 
Figure 3 Kaplan-Meier survival curves of all-cause mortality. 
(A) The unadjusted Kaplan-Meier survival curves of all cause of mortality that estimated the 
mortality rate in ICH operative patients using real-world data. Log-Rank test demonstrated p 
< 0.001 for all antiplatelet vs control, anticoagulant vs control, anticoagulant vs antiplatelet, 
and antiplatelet vs control. (B-C) The matched control Kaplan-Meier survival curves of all 
cause of mortality estimated the mortality rate patients between different cohorts. Adjusted 
incidence curves were adjusted for all covariates listed in Table 1. P of log-Rank test 
demonstrated p=0.001 for anticoagulant vs control (B), p = 0.007 for anticoagulant vs 
antiplatelet (C), and p =0.773 for antiplatelet vs control (D). 
 
Table 1. Baseline and clinical characteristics of the study patients before propensity score 
matching 
 
Table 2. Descriptive statistics of in-hospital treatment, complication and mortality of the study 
patients 
 
Table 3. In-hospital treatment of the study patients 
 
Table 4. In-hospital complication and mortality of the study patients  
 
Supplementary Table 1. ICD-9-CM code used in the current study. 
Supplementary Table 2. Baseline and clinical characteristics in the antiplatelet and control 
groups after propensity score matching. 
Supplementary Table 3. Baseline and clinical characteristics in the anticoagulant and control 
groups after propensity score matching. 
Supplementary Table 4. Baseline and clinical characteristics in the anticoagulant and 
antiplatelet groups after propensity score matching. 
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Table 1 
Variable 
Total 
(n = 
18,872) 
Control 
(n = 
16,251) 
Antiplatelet  
(n = 2,267) 
Anticoagulant 
 (n = 354) 
Gender     
Male 12,548 
(66.5) 
10,939 
(67.3) 
1,413 
(62.3)a 
196 (55.4)ab 
Female 6,324 
(33.5) 
5,312 
(32.7) 
854 (37.7)a 158 (44.6)ab 
Age (years) 59.7±13.8 58.6±13.8 66.6±11.7a 65.3±13.5a 
Age group     
20-39 years 1,404 (7.4) 1,349 (8.3) 35 (1.5)a 20 (5.6)b 
40-59 years 8,430 
(44.7) 
7,721 
(47.5) 
613 (27.0)a 96 (27.1)a 
60-79 years 7,670 
(40.6) 
6,123 
(37.7) 
1,354 
(59.7)a 
193 (54.5)a 
≥ 80 years 1,368 (7.2) 1,058 (6.5) 265 (11.7)a 45 (12.7)a 
Operation in teaching 
hospital 
    
No 11,796 
(62.5) 
10,249 
(63.1) 
1,386 
(61.1) 
161 (45.5)ab 
Yes 7,076 
(37.5) 
6,002 
(36.9) 
881 (38.9) 193 (54.5)ab 
Coexisting disease     
Atrial fibrillation 470 (2.5) 161 (1.0) 145 (6.4)a 164 (46.3)ab 
Dementia 242 (1.3) 164 (1.0) 70 (3.1)a 8 (2.3) 
Epilepsy 425 (2.3) 334 (2.1) 84 (3.7)a 7 (2.0) 
Hypertension 5,939 
(31.5) 
3,945 
(24.3) 
1,731 
(76.4)a 
263 (74.3)a 
Diabetes mellitus 1,907 
(10.1) 
1,159 (7.1) 669 (29.5)a 79 (22.3)ab 
Coronary artery 
disease 
1,915 
(10.1) 
947 (5.8) 844 (37.2)a 124 (35.0)a 
Peripheral arterial 
disease 
269 (1.4) 131 (0.8) 111 (4.9)a 27 (7.6)a 
Dialysis 476 (2.5) 382 (2.4) 80 (3.5)a 14 (4.0) 
Chronic kidney 898 (4.8) 680 (4.2) 184 (8.1)a 34 (9.6)a 
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Table 1. Baseline and clinical characteristics of the study patients before propensity 
score matching 
Data are presented as frequency with percentage in brackets, or mean ± standard 
deviation. NIHSS, National Institute of Health Stroke Scale; The characters “a” and 
“b” denote a significant post hoc comparison versus control and antiplatelet, 
respectively.  
  
disease 
History of event     
Ischemic stroke 750 (4.0) 466 (2.9) 244 (10.8)a 40 (11.3)a 
Intracranial 
hemorrhage 
427 (2.3) 340 (2.1) 79 (3.5)a 8 (2.3) 
Myocardial infarction 206 (1.1) 98 (0.6) 94 (4.1)a 14 (4.0)a 
Charlson Comorbidity 
Index 
2.0 ± 1.3 1.9 ± 1.2 2.5 ± 1.5a 2.7 ± 1.7ab 
Estimated NIHSS 22.5 ± 3.5 22.4 ± 3.5 22.9 ± 3.5a 22.8 ± 3.4 
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Table 2. In-hospital treatment, complication and mortality of the study patients during 
index date hospitalization 
 Propensity score matched cohort 
 
Antiplatelet  
vs. Control 
(n = 1,626  
for each cohort) 
 
Anticoagulant  
vs. Control 
(n = 281  
for each cohort) 
 Anticoagulant  
vs. Antiplatelet 
(n = 293  
for each cohort) 
Outcome 
Anti-
platelet Control  
Anti-
coagula
nt Control 
 
Anti-
coagulant 
Anti-
platelet 
Neurosurgical 
procedure 
        
Craniectomy 148 (9.1) 121 (7.4)  34 
(12.1) 
27 (9.6)  39 (13.3) 19 (6.5) 
Repeated brain 
surgery 
165 
(10.1) 
132 (8.1)  36 
(12.8) 
27 (9.6)  41 (14.0) 22 (7.5) 
EVD 290 
(17.8) 
299 (18.4)  55 
(19.6) 
54 (19.2)  61 (20.8) 57 (19.5) 
V-P shunt 56 (3.4) 56 (3.4)  6 (2.1) 11 (3.9)  6 (2.0) 8 (2.7) 
Blood transfusion, 
U 
        
Platelet 1.8 ± 7.1 1.1 ± 4.9  2.1 ± 6.0 2.1 ± 7.8  2.2 ± 6.4 2.8 ± 9.1 
Fresh frozen 
plasma 
2.5 ± 6.8 2.0 ± 4.7  5.6 ± 6.2 2.3 ± 4.9  5.5 ± 6.1 3.0 ± 9.1 
PRBC 1.6 ± 2.5 1.4 ± 2.2  2.1 ± 2.7 1.9 ± 3.2  2.2 ± 2.8 1.9 ± 3.0 
Complications         
Ischemic stroke 78 (4.8) 64 (3.9)  18 (6.4) 10 (3.6)  19 (6.5) 25 (8.5) 
Pneumonia 398 
(24.5) 
412 (25.3)  82 
(29.2) 
68 (24.2)  84 (28.7) 69 (23.5) 
Septicemia 80 (4.9) 78 (4.8)  22 (7.8) 14 (5.0)  24 (8.2) 11 (3.8) 
Wound 
infection 
11 (0.7) 20 (1.2)  4 (1.4) 3 (1.1)  5 (1.7) 1 (0.3) 
Pulmonary 
embolism 
4 (0.2) 2 (0.1)  1 (0.4) 0 (0.0)  1 (0.3) 0 (0.0) 
Deep vein 
thrombosis 
5 (0.3) 5 (0.3)  3 (1.1) 1 (0.4)  3 (1.0) 0 (0.0) 
Acute kidney 
injury 
62 (3.8) 66 (4.1)  10 (3.6) 11 (3.9)  11 (3.8) 11 (3.8) 
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 Propensity score matched cohort 
 
Antiplatelet  
vs. Control 
(n = 1,626  
for each cohort) 
 
Anticoagulant  
vs. Control 
(n = 281  
for each cohort) 
 Anticoagulant  
vs. Antiplatelet 
(n = 293  
for each cohort) 
Outcome 
Anti-
platelet Control  
Anti-
coagula
nt Control 
 
Anti-
coagulant 
Anti-
platelet 
Massive blood 
transfusion 
(PRBC > 10 U) 
22 (1.4) 14 (0.9)  5 (1.8) 9 (3.2)  5 (1.7) 4 (1.4) 
Any 
complications 
630 
(38.7) 
629 (38.7)  127 
(45.2) 
112 (39.9)  136 (46.4) 113 (38.6) 
In-hospital 
mortality 
384 
(23.6) 
372 (22.9)  97 
(34.5) 
56 (19.9)  98 (33.4) 70 (23.9) 
Data are presented as frequency with percentage in brackets, or mean ± standard 
deviation. EVD, extra-ventricular drainage; V-P, ventriculoperitoneal; PRBC, packed 
red blood cell. 
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Table 3. In-hospital neurosurgical and blood transfusion procedures in the study 
patients  
 Odds ratio or regression coefficient and 95% CI 
 
Antiplatelet  
vs. Control 
(n = 1,626  
for each cohort) 
 
Anticoagulant  
vs. Control 
(n = 281  
for each cohort) 
 Anticoagulant 
vs. Antiplatelet 
(n = 293  
for each cohort) 
Outcome 
OR / B 
(95% CI) 
P 
value  
OR / B  
(95% CI) 
P 
value 
 OR / B  
(95% CI) 
P 
value 
Neurosurgical 
procedure 
   
   
  
Craniectomy 1.25  
(0.97–1.60) 
0.086  
1.30  
(0.76–2.21) 
0.344 
 2.21  
(1.25–3.93) 
0.007 
Repeated brain 
surgery 
1.28  
(1.01 – 
1.63) 
0.045  
1.38  
(0.81 – 
2.35) 
0.230 
 2.00  
(1.16 – 
3.46) 
0.013 
EVD 0.96  
(0.81–1.15) 
0.682  
1.02  
(0.67–1.55) 
0.915 
 1.09  
(0.73–1.63) 
0.680 
V-P shunt 1.00  
(0.69–1.46) 
1.000  
0.54  
(0.20–1.47) 
0.225 
 0.75  
(0.26–2.17) 
0.590 
Blood transfusion, U         
Platelet 
0.70  
(0.28–1.12) 
0.001  
-0.04  
(-1.20–
1.12) 
0.945 
 -0.55  
(-1.82–
0.72) 
0.393 
Fresh frozen 
plasma 
0.51  
(0.10–0.91) 
0.014  
3.30  
(2.38–4.22) 
<0.00
1 
 2.59  
(1.33–3.85) 
<0.00
1 
PRBC 
0.23  
(0.07–0.39) 
0.006  
0.23  
(-0.26–
0.71) 
0.358 
 0.32  
(-0.15–
0.78) 
0.185 
OR, odds ratio; B, regression coefficient; CI, confidence interval; EVD, extra-
ventricular drainage; V-P, ventriculoperitoneal; PRBC, packed red blood cell. 
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Table 4. In-hospital complication and mortality of the study patients 
 Odds ratio and 95% CI 
 
Antiplatelet  
vs. Control 
(n = 1,626  
for each cohort) 
 
Anticoagulant  
vs. Control 
(n = 281  
for each cohort) 
 Anticoagulant  
vs. Antiplatelet 
(n = 293  
for each cohort) 
Outcome 
OR  
(95% CI) 
P 
value  
OR  
(95% CI) 
P 
value 
 OR  
(95% CI) 
P 
value 
Complications         
Ischemic stroke 1.23  
(0.88–1.72) 
0.230  1.86  
(0.84–4.09) 
0.126  0.74  
(0.40–1.38) 
0.348 
Pneumonia 0.96  
(0.82–1.12) 
0.570  1.29  
(0.89–1.88) 
0.182  1.31  
(0.90–1.89) 
0.159 
Septicemia 1.03  
(0.75–1.41) 
0.870  1.62  
(0.81–3.24) 
0.172  2.29  
(1.10–4.76) 
0.027 
Wound 
infection 
0.55  
(0.26–1.15) 
0.110  1.34  
(0.30–6.03) 
0.705  5.07  
(0.59–43.66) 
0.140 
Pulmonary 
embolism 
2.00  
(0.37–
10.95) 
0.423  NA NA  NA NA 
Deep vein 
thrombosis 
1.00  
(0.29–3.46) 
1.000  3.02  
(0.31–
29.22) 
0.340  NA NA 
Acute kidney 
injury 
0.94  
(0.66–1.34) 
0.718  0.91  
(0.38–2.17) 
0.824  1.00  
(0.43–2.34) 
1.000 
Massive blood 
transfusion 
(PRBC > 10 U) 
1.58  
(0.81–3.10) 
0.184  0.55  
(0.18–1.66) 
0.286  1.25  
(0.33–4.72) 
0.737 
Any 
complications 
1.00  
(0.87–1.16) 
0.971  1.24 
(0.89–1.74) 
0.201  1.38  
(0.99–1.92) 
0.055 
In-hospital 
mortality 
1.04  
(0.89–1.23) 
0.618  2.12  
(1.45–3.10) 
<0.00
1 
 1.60  
(1.12–2.30) 
0.011 
OR, odds ratio; CI, confidence interval; PRBC, packed red blood cell; NA, not 
applicable. 
 
 
 
